To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. All cases were documented on large-format histology slides. The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. The corresponding figures in the lobular group were 27.8% (37/133), 45.9% (61/586), and 26.3% (35/133), respectively. When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. The corresponding figures in the lobular category were 15.0% (20/133), 54.2% (72/133), and 30.8% (41/133), respectively. Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. All these differences were statistically highly significant ( ). While the histological tumor type itself (ductal versus lobular) did not influence the lymph node status, multifocal and diffuse distribution of the lesions were associated with significantly increased risk of lymph node metastases in both ductal and lobular cancers. 1. Introduction Breast cancer is a heterogeneous disease in which the individual cases deviate from each other in morphology, protein expression, molecular phenotype, genetic characteristics, and prognosis. Breast carcinomas of “special-types” have been delineated based on their microscopical characteristics, but the vast majority of tumors belongs to the category of not otherwise specified (NOS) ductal carcinomas. Invasive lobular carcinomas represent the most frequent “special-type” breast carcinoma and comprise 5–15% of all breast cancer cases [1]. In addition both the ductal and the lobular tumors also represent heterogeneous groups of diseases and can be prognostically stratified with grading or delineating distinct histological subtypes. Numerous studies have compared ductal and lobular breast carcinomas using different criteria, and reported more [2, 3] or less favourable [4, 5] outcome in lobular compared to ductal carcinomas, or no significant differences in outcome [6, 7]. On the other hand, studies on subgross morphology (lesion distribution and disease extent) of these tumors are very rare. Tot has previously described the diffuse variant of invasive lobular carcinoma and reported a poorer prognosis when compared to unifocal and multifocal lobular cancers [8]. Foschini
References
[1]
S. R. Lakhani, I. O. Ellis, S. J. Schnitt, et al., Eds., WHO Classification of Tumours of the Breast, International Agancy for Research on Cancer, Lyon, France, 2012.
[2]
J. M. Dixon, T. J. Anderson, D. L. Page, et al., “Infiltrating lobular carcinoma of the breast,” Histopathology, vol. 6, no. 2, pp. 149–161, 1982.
[3]
R. S. Du Toit, A. P. Locker, I. O. Ellis, C. W. Elston, R. I. Nicholson, and R. W. Blamey, “Invasive lobular carcinomas of the breast—the prognosis of histopathological subtypes,” British Journal of Cancer, vol. 60, no. 4, pp. 605–609, 1989.
[4]
R. Ashikari, A. G. Huvos, J. A. Urban, and G. F. Robbins, “Infiltrating lobular carcinoma of the breast,” Cancer, vol. 31, no. 1, pp. 110–116, 1973.
[5]
B. C. Pestalozzi, D. Zahrieh, E. Mallon et al., “Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3006–3014, 2008.
[6]
G. Arpino, V. J. Bardou, G. M. Clark, and R. M. Elledge, “Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome,” Breast Cancer Research, vol. 6, no. 3, pp. R149–R156, 2004.
[7]
T. Korhonen, H. Huhtala, and K. Holli, “A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast,” Breast Cancer Research and Treatment, vol. 85, no. 1, pp. 23–29, 2004.
[8]
T. Tot, “The diffuse type of invasive lobular carcinoma of the breast: morphology and prognosis,” Virchows Archiv, vol. 443, no. 6, pp. 718–724, 2003.
[9]
M. P. Foschini, A. Righi, M. C. Cucchi et al., “The impact of large sections and 3D technique on the study of lobular in situ and invasive carcinoma of the breast,” Virchows Archiv, vol. 448, no. 3, pp. 256–261, 2006.
[10]
M. P. Foschini, F. Flamminio, R. Miglio et al., “The impact of large sections on the study of in situ and invasive duct carcinoma of the breast,” Human Pathology, vol. 38, no. 12, pp. 1736–1743, 2007.
[11]
J. Boyages, U. W. Jayasinghe, and N. Coombs, “Multifocal breast cancer and survival: each focus does matter particularly for larger tumours,” European Journal of Cancer, vol. 46, no. 11, pp. 1990–1996, 2010.
[12]
T. M. Weissenbacher, M. Zschage, W. Janni et al., “Multicentric and multifocal versus unifocal breast cancer: Is the tumor-node-metastasis classification justified?” Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 27–34, 2010.
[13]
T. Tot, M. Gere, G. Pekár et al., “Breast cancer multifocality, disease extent, and survival,” Human Pathology, vol. 42, no. 11, pp. 1761–1769, 2011.
[14]
T. Tot, “Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections,” Cancer, vol. 110, no. 11, pp. 2551–2560, 2007.
[15]
T. Tot, L. Tabár, and P. B. Dean, Practical Breast Pathology, Thieme, Stuttgart, Germany, 2002.
[16]
D. Lindquist, “Disease extent ≥ 4？cm is a prognostic marker of local recurrence in T1-2 breast cancer,” Pathology Research International, vol. 2011, Article ID 860584, 2011.
[17]
AJCC Cancer Staging Handbook, Springer, New York, NY, USA, 7th edition, 2010.
[18]
M. Boros, C. Marian, C. Moldovan, and S. Stolnicu, “Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas,” Pathology Research and Practice. In press.
[19]
T. Tot, “The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases,” International Journal of Breast Cancer. In press.
[20]
A. A. Andea, T. Wallis, L. A. Newman, D. Bouwman, J. Dey, and D. W. Visscher, “Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma,” Cancer, vol. 94, no. 5, pp. 1383–1390, 2002.
[21]
A. A. Andea, D. Bouwman, T. Wallis, and D. W. Visscher, “Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma,” Cancer, vol. 100, no. 1, pp. 20–27, 2004.
[22]
N. Cabioglu, V. Ozmen, H. Kaya et al., “Increased lymph node positivity in multifocal and multicentric breast cancer,” Journal of the American College of Surgeons, vol. 208, no. 1, pp. 67–74, 2009.
[23]
T. Tot, “Axillary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: differences are related to macrometastatic disease,” Annals of Surgical Oncology, vol. 19, no. 11, pp. 3395–3401, 2012.
